Toxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Review

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorOLIVEIRA, Mariana Campello de
dc.contributor.authorVIDES, Mariana Capelo
dc.contributor.authorLASSI, Dangela Layne Silva
dc.contributor.authorTORALES, Julio
dc.contributor.authorVENTRIGLIO, Antonio
dc.contributor.authorBOMBANA, Henrique Silva
dc.contributor.authorLEYTON, Vilma
dc.contributor.authorPERICO, Cintia de Azevedo-Marques
dc.contributor.authorNEGRAO, Andre Brooking
dc.contributor.authorMALBERGIER, Andre
dc.contributor.authorCASTALDELLI-MAIA, Joao Mauricio
dc.date.accessioned2023-08-16T17:50:01Z
dc.date.available2023-08-16T17:50:01Z
dc.date.issued2023
dc.description.abstract(1) Background: Synthetic cannabinoids (SCs) are emerging drugs of abuse sold as 'K2', 'K9' or 'Spice'. Evidence shows that using SCs products leads to greater health risks than cannabis. They have been associated with greater toxicity and higher addiction potential unrelated to the primary psychoactive component of marijuana, & UDelta;9-tetrahydrocannabinol (& UDelta;9-THC). Moreover, early cases of intoxication and death related to SCs highlight the inherent danger that may accompany the use of these substances. However, there is limited knowledge of the toxicology of Spice ingredients. This systematic review intends to analyze the toxicity of SCs compounds in Spice/K2 drugs. (2) Methods: Studies analyzing synthetic cannabinoid toxicity and dependence were included in the present review. We searched the PubMed database of the US National Library of Medicine, Google Scholar, CompTox Chemicals, and Web of Science up to May 2022. (3) Results: Sixty-four articles reporting the effects of synthetic cannabinoids in humans were included in our review. Ten original papers and fifty-four case studies were also included. Fourteen studies reported death associated with synthetic cannabinoid use, with AB-CHMINACA and MDMB-CHMICA being the main reported SCs. Tachycardia and seizures were the most common toxicity symptoms. The prevalence of neuropsychiatric symptoms was higher in third-generation SCs. (4) Conclusion: SCs may exhibit higher toxicity than THC and longer-lasting effects. Their use may be harmful, especially in people with epilepsy and schizophrenia, because of the increased risk of the precipitation of psychiatric and neurologic disorders. Compared to other drugs, SCs have a higher potential to trigger a convulsive crisis, a decline in consciousness, and hemodynamic changes. Therefore, it is crucial to clarify their potential harms and increase the availability of toxicology data in both clinical and research settings.eng
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.identifier.citationBRAIN SCIENCES, v.13, n.7, article ID 990, 17p, 2023
dc.identifier.doi10.3390/brainsci13070990
dc.identifier.eissn2076-3425
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/54709
dc.language.isoeng
dc.publisherMDPIeng
dc.relation.ispartofBrain Sciences
dc.rightsopenAccesseng
dc.rights.holderCopyright MDPIeng
dc.subjectsynthetic cannabinoideng
dc.subjectSpiceeng
dc.subjectK2eng
dc.subjectJWHeng
dc.subjectAMeng
dc.subjectRCSeng
dc.subjectHUeng
dc.subjectAB-PINACAeng
dc.subjectAPICAeng
dc.subjectMAMeng
dc.subjectCHMICAeng
dc.subjectUReng
dc.subjectXLReng
dc.subjectAKBeng
dc.subjectAB-FUBINACAeng
dc.subjectADBeng
dc.subjectEAMeng
dc.subjectWINeng
dc.subjectPBeng
dc.subjectMDMBeng
dc.subject.otherfatal intoxicationeng
dc.subject.otherab-fubinacaeng
dc.subject.otherreceptor agonistseng
dc.subject.otherischemic-strokeeng
dc.subject.otheradb-fubinacaeng
dc.subject.othermdmb-chmicaeng
dc.subject.otherconsumptioneng
dc.subject.otherchminacaeng
dc.subject.otherspiceeng
dc.subject.otherdeatheng
dc.subject.wosNeuroscienceseng
dc.titleToxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Revieweng
dc.typearticleeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryParaguai
hcfmusp.affiliation.countryItália
hcfmusp.affiliation.countryisopy
hcfmusp.affiliation.countryisoit
hcfmusp.author.externalTORALES, Julio:Natl Univ Asuncion, Sch Med Sci, Dept Psychol Med, San Lorenzo 111421, Paraguay
hcfmusp.author.externalVENTRIGLIO, Antonio:Univ Foggia, Med Sch, Dept Expt Med, I-71122 Foggia, Italy
hcfmusp.author.externalPERICO, Cintia de Azevedo-Marques:FMABC Univ Ctr, Med Sch, Dept Neurosci, BR-09060870 Santo Andre, SP, Brazil
hcfmusp.citation.scopus4
hcfmusp.contributor.author-fmusphcMARIANA CAMPELLO DE OLIVEIRA
hcfmusp.contributor.author-fmusphcMARIANA CAPELO VIDES
hcfmusp.contributor.author-fmusphcDANGELA LAYNE SILVA LASSI
hcfmusp.contributor.author-fmusphcHENRIQUE SILVA BOMBANA
hcfmusp.contributor.author-fmusphcVILMA LEYTON
hcfmusp.contributor.author-fmusphcANDRE BROOKING NEGRAO
hcfmusp.contributor.author-fmusphcANDRE MALBERGIER
hcfmusp.contributor.author-fmusphcJOAO MAURICIO CASTALDELLI MAIA
hcfmusp.description.articlenumber990
hcfmusp.description.issue7
hcfmusp.description.volume13
hcfmusp.origemWOS
hcfmusp.origem.pubmed37508922
hcfmusp.origem.scopus2-s2.0-85166398755
hcfmusp.origem.wosWOS:001035184700001
hcfmusp.publisher.cityBASELeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAbouchedid R, 2017, CLIN TOXICOL, V55, P338, DOI 10.1080/15563650.2017.1287373eng
hcfmusp.relation.referenceAbouchedid R, 2016, J MED TOXICOL, V12, P396, DOI 10.1007/s13181-016-0571-7eng
hcfmusp.relation.referenceAdamowicz P, 2016, CLIN TOXICOL, V54, P650, DOI 10.1080/15563650.2016.1190016eng
hcfmusp.relation.referenceAdamowicz P, 2016, FORENSIC SCI INT, V261, pE5, DOI 10.1016/j.forsciint.2016.02.024eng
hcfmusp.relation.referenceAl Fawaz S, 2019, AM J CASE REP, V20, P1902, DOI 10.12659/AJCR.918918eng
hcfmusp.relation.referenceAmerican Psychiatric Association,, 2013, DIAGN STAT MAN MENT, V5th, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596.744053]eng
hcfmusp.relation.referenceAngerer V, 2017, FORENSIC SCI INT, V281, pE9, DOI 10.1016/j.forsciint.2017.10.042eng
hcfmusp.relation.referenceBackberg M, 2017, J MED TOXICOL, V13, P52, DOI 10.1007/s13181-016-0584-2eng
hcfmusp.relation.referenceBarcelo B, 2017, FORENSIC SCI INT, V273, pE10, DOI 10.1016/j.forsciint.2017.01.020eng
hcfmusp.relation.referenceBehonick G, 2014, J ANAL TOXICOL, V38, P559, DOI 10.1093/jat/bku048eng
hcfmusp.relation.referenceBrandehoff N, 2018, CLIN TOXICOL, V56, P193, DOI 10.1080/15563650.2017.1357826eng
hcfmusp.relation.referenceTyndall JA, 2015, CLIN TOXICOL, V53, P950, DOI 10.3109/15563650.2015.1100306eng
hcfmusp.relation.referenceUnited Nations Office on Drugs and Crime, WORLD DRUG REPORT 20eng
hcfmusp.relation.referenceUsui K, 2018, J ANAL TOXICOL, V42, pE21, DOI 10.1093/jat/bkx088eng
hcfmusp.relation.referenceWestin AA, 2016, J ANAL TOXICOL, V40, P86, DOI 10.1093/jat/bkv110eng
hcfmusp.relation.referenceWikstrom M, 2013, J ANAL TOXICOL, V37, P43, DOI 10.1093/jat/bks086eng
hcfmusp.relation.referenceWiley JL, 2014, LIFE SCI, V97, P55, DOI 10.1016/j.lfs.2013.09.011eng
hcfmusp.relation.referenceYamagishi I, 2018, LEGAL MED-TOKYO, V35, P44, DOI 10.1016/j.legalmed.2018.08.004eng
hcfmusp.relation.referenceYoung AC, 2012, AM J EMERG MED, V30, DOI 10.1016/j.ajem.2011.05.013eng
hcfmusp.relation.referenceZaami S, 2018, EUR REV MED PHARMACO, V22, P268, DOI 10.26355/eurrev_201801_14129eng
hcfmusp.relation.referenceBrents LK, 2014, DRUG METAB REV, V46, P72, DOI 10.3109/03602532.2013.839700eng
hcfmusp.relation.referenceBuser GL, 2014, CLIN TOXICOL, V52, P664, DOI 10.3109/15563650.2014.932365eng
hcfmusp.relation.referenceCannaert A, 2020, ACS CHEM NEUROSCI, V11, P4434, DOI 10.1021/acschemneuro.0c00644eng
hcfmusp.relation.referenceCastaneto MS, 2014, DRUG ALCOHOL DEPEN, V144, P12, DOI 10.1016/j.drugalcdep.2014.08.005eng
hcfmusp.relation.referenceCelofiga A, 2014, J DUAL DIAGN, V10, P168, DOI 10.1080/15504263.2014.929364eng
hcfmusp.relation.referenceChan SJ, 2019, FORENSIC SCI INT, V304, DOI 10.1016/j.forsciint.2019.109892eng
hcfmusp.relation.referenceChan WL, 2013, J MED TOXICOL, V9, P278, DOI 10.1007/s13181-013-0306-yeng
hcfmusp.relation.referenceColizzi M, 2016, NEUROSCI BIOBEHAV R, V64, P359, DOI 10.1016/j.neubiorev.2016.03.010eng
hcfmusp.relation.referenceCoppola M, 2017, J PSYCHOACTIVE DRUGS, V49, P262, DOI 10.1080/02791072.2017.1316431eng
hcfmusp.relation.referenceDebruyne D, 2015, SUBST ABUSE REHABIL, V6, P113, DOI 10.2147/SAR.S73586eng
hcfmusp.relation.referenceDeng HQ, 2018, PSYCHIAT RES, V268, P400, DOI 10.1016/j.psychres.2018.08.012eng
hcfmusp.relation.referenceEuropean Monitoring Centre for Drugs and Drug Addiction, 2009, RISK ASS NEW PSYCH Seng
hcfmusp.relation.referenceEuropean Monitoring Centre for Drugs and Drugs Addiction, 2017, PERSP DRUGS SYNTH CAeng
hcfmusp.relation.referenceEvery-Palmer S, 2011, DRUG ALCOHOL DEPEN, V117, P152, DOI 10.1016/j.drugalcdep.2011.01.012eng
hcfmusp.relation.referenceEvery-Palmer S, 2010, ADDICTION, V105, P1859, DOI 10.1111/j.1360-0443.2010.03119.xeng
hcfmusp.relation.referenceFantegrossi WE, 2018, DRUG METAB REV, V50, P65, DOI 10.1080/03602532.2018.1428343eng
hcfmusp.relation.referenceFantegrossi WE, 2014, LIFE SCI, V97, P45, DOI 10.1016/j.lfs.2013.09.017eng
hcfmusp.relation.referenceFattore L, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00060eng
hcfmusp.relation.referenceFerrari E, 2022, FRONT TOXICOL, V4, DOI 10.3389/ftox.2022.1033733eng
hcfmusp.relation.referenceFreeman MJ, 2013, NEUROLOGY, V81, P2090, DOI 10.1212/01.wnl.0000437297.05570.a2eng
hcfmusp.relation.referenceGaunitz F, 2022, INT J LEGAL MED, V136, P577, DOI 10.1007/s00414-021-02717-6eng
hcfmusp.relation.referenceGaunitz F, 2018, INT J LEGAL MED, V132, P1645, DOI 10.1007/s00414-018-1911-8eng
hcfmusp.relation.referenceGiorgetti A, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00464eng
hcfmusp.relation.referenceGugelmann H, 2014, CLIN TOXICOL, V52, P635, DOI 10.3109/15563650.2014.925562eng
hcfmusp.relation.referenceHermanns-Clausen M, 2018, CLIN TOXICOL, V56, P404, DOI 10.1080/15563650.2017.1393082eng
hcfmusp.relation.referenceHermanns-Clausen M, 2013, ADDICTION, V108, P534, DOI 10.1111/j.1360-0443.2012.04078.xeng
hcfmusp.relation.referenceHess C, 2015, FORENSIC SCI INT, V257, pE6, DOI 10.1016/j.forsciint.2015.08.012eng
hcfmusp.relation.referenceHopkins CY, 2013, J EMERG MED, V45, P544, DOI 10.1016/j.jemermed.2012.11.034eng
hcfmusp.relation.referenceHudson S, 2011, DRUG TEST ANAL, V3, P466, DOI 10.1002/dta.268eng
hcfmusp.relation.referenceHuffman JW, 2005, BIOORGAN MED CHEM, V13, P89, DOI 10.1016/j.bmc.2004.09.050eng
hcfmusp.relation.referenceHvozdovich JA, 2020, J ANAL TOXICOL, V44, P298, DOI 10.1093/jat/bkz092eng
hcfmusp.relation.referenceIvanov ID, 2019, FORENSIC SCI INT, V297, P372, DOI 10.1016/j.forsciint.2019.02.005eng
hcfmusp.relation.referenceKALIX P, 1981, PSYCHOPHARMACOLOGY, V74, P269, DOI 10.1007/BF00427108eng
hcfmusp.relation.referenceKamijo Y, 2016, AM J DRUG ALCOHOL AB, V42, P513, DOI 10.1080/00952990.2016.1176177eng
hcfmusp.relation.referenceKlavz J, 2016, FORENSIC SCI INT, V265, P121, DOI 10.1016/j.forsciint.2016.01.018eng
hcfmusp.relation.referenceKovacs K, 2019, J FORENSIC LEG MED, V65, P92, DOI 10.1016/j.jflm.2019.04.012eng
hcfmusp.relation.referenceKraemer M, 2019, FORENSIC SCI INT, V301, pE29, DOI 10.1016/j.forsciint.2019.05.017eng
hcfmusp.relation.referenceKraemer M, 2019, FORENSIC SCI INT, V298, P186, DOI 10.1016/j.forsciint.2019.02.021eng
hcfmusp.relation.referenceKrotulski AJ, 2021, DRUG TEST ANAL, V13, P427, DOI 10.1002/dta.2935eng
hcfmusp.relation.referenceLam RPK, 2017, CLIN TOXICOL, V55, P662, DOI 10.1080/15563650.2017.1307385eng
hcfmusp.relation.referenceLangford AM, 2018, J FORENSIC LEG MED, V59, P36, DOI 10.1016/j.jflm.2018.07.012eng
hcfmusp.relation.referenceLapoint J, 2011, CLIN TOXICOL, V49, P760, DOI 10.3109/15563650.2011.609822eng
hcfmusp.relation.referenceLe Boisselier R, 2017, CLIN PHARMACOL THER, V101, P220, DOI 10.1002/cpt.563eng
hcfmusp.relation.referenceLehmann S, 2020, INT J LEGAL MED, V134, P229, DOI 10.1007/s00414-019-02193-zeng
hcfmusp.relation.referenceLemos NP, 2014, J FORENSIC SCI, V59, P1679, DOI 10.1111/1556-4029.12550eng
hcfmusp.relation.referenceLonati D, 2014, ANN EMERG MED, V64, P629, DOI 10.1016/j.annemergmed.2014.01.007eng
hcfmusp.relation.referenceMaeda H, 2018, CLIN TOXICOL, V56, P143, DOI 10.1080/15563650.2017.1340648eng
hcfmusp.relation.referenceMalaca S, 2022, CURR PHARM DESIGN, V28, P2603, DOI 10.2174/1381612827666211115170521eng
hcfmusp.relation.referenceManini AF, 2022, CLIN TOXICOL, V60, P524, DOI 10.1080/15563650.2021.1975734eng
hcfmusp.relation.referenceMcQuade D, 2013, EUR J CLIN PHARMACOL, V69, P373, DOI 10.1007/s00228-012-1379-2eng
hcfmusp.relation.referenceMeyyappan C, 2017, CLIN TOXICOL, V55, P151, DOI 10.1080/15563650.2016.1227832eng
hcfmusp.relation.referenceMoeller S, 2017, ASIAN J PSYCHIATR, V25, P127, DOI 10.1016/j.ajp.2016.10.019eng
hcfmusp.relation.referenceMoher D, 2009, PHYS THER, V89, P873, DOI 10.1093/ptj/89.9.873eng
hcfmusp.relation.referenceMontanari E, 2022, THER DRUG MONIT, V44, P494, DOI 10.1097/FTD.0000000000000970eng
hcfmusp.relation.referenceMusshoff F, 2014, INT J LEGAL MED, V128, P59, DOI 10.1007/s00414-013-0864-1eng
hcfmusp.relation.referenceNacca N, 2018, J EMERG MED, V55, P788, DOI 10.1016/j.jemermed.2018.09.012eng
hcfmusp.relation.referencePacher P, 2018, NAT REV CARDIOL, V15, P151, DOI 10.1038/nrcardio.2017.130eng
hcfmusp.relation.referencePalamar JJ, 2015, DRUG ALCOHOL DEPEN, V149, P194, DOI 10.1016/j.drugalcdep.2015.01.044eng
hcfmusp.relation.referencePant S, 2012, AM J MED SCI, V344, P67, DOI 10.1097/MAJ.0b013e31824cf5c2eng
hcfmusp.relation.referencePapanti D, 2013, HUM PSYCHOPHARM CLIN, V28, P379, DOI 10.1002/hup.2312eng
hcfmusp.relation.referencePatton AL, 2013, J FORENSIC SCI, V58, P1676, DOI 10.1111/1556-4029.12216eng
hcfmusp.relation.referencePaul ABM, 2018, J FORENSIC SCI, V63, P1321, DOI 10.1111/1556-4029.13704eng
hcfmusp.relation.referencePeterson BL, 2015, J ANAL TOXICOL, V39, P642, DOI 10.1093/jat/bkv091eng
hcfmusp.relation.referencePintori N, 2017, BEHAV PHARMACOL, V28, P409, DOI 10.1097/FBP.0000000000000323eng
hcfmusp.relation.referenceRoberts J.R., 2015, EMERG MED NEWS, V37, P12eng
hcfmusp.relation.referenceRojek S, 2017, LEGAL MED-TOKYO, V27, P25, DOI 10.1016/j.legalmed.2017.06.004eng
hcfmusp.relation.referenceSalle S, 2021, INT J LEGAL MED, V135, P1467, DOI 10.1007/s00414-021-02561-8eng
hcfmusp.relation.referenceSchneir AB, 2011, J EMERG MED, V40, P296, DOI 10.1016/j.jemermed.2010.10.014eng
hcfmusp.relation.referenceSchwartz MD, 2015, J EMERG MED, V48, P573, DOI 10.1016/j.jemermed.2014.12.038eng
hcfmusp.relation.referenceSeywright A, 2016, CLIN TOXICOL, V54, P632, DOI 10.1080/15563650.2016.1186805eng
hcfmusp.relation.referenceShanks KG, 2016, J ANAL TOXICOL, V40, P236, DOI 10.1093/jat/bkv142eng
hcfmusp.relation.referenceShanks KG, 2015, FORENSIC SCI INT, V252, pE6, DOI 10.1016/j.forsciint.2015.04.021eng
hcfmusp.relation.referenceSimon G, 2022, LEGAL MED-TOKYO, V54, DOI 10.1016/j.legalmed.2021.102004eng
hcfmusp.relation.referenceSpaderna M, 2013, PSYCHOPHARMACOLOGY, V228, P525, DOI 10.1007/s00213-013-3188-4eng
hcfmusp.relation.referenceTai Sherrica, 2014, Curr Addict Rep, V1, P129eng
hcfmusp.relation.referenceTait RJ, 2016, CLIN TOXICOL, V54, P1, DOI 10.3109/15563650.2015.1110590eng
hcfmusp.relation.referenceTakematsu M, 2014, CLIN TOXICOL, V52, P973, DOI 10.3109/15563650.2014.958614eng
hcfmusp.relation.referenceTebo C, 2019, AM J EMERG MED, V37, P1846, DOI 10.1016/j.ajem.2018.12.044eng
hcfmusp.relation.referenceTheunissen EL, 2022, PSYCHOPHARMACOLOGY, V239, P1251, DOI 10.1007/s00213-021-05768-0eng
hcfmusp.relation.referenceTheunissen EL, 2018, BRIT J PHARMACOL, V175, P18, DOI 10.1111/bph.14066eng
hcfmusp.relation.referenceTheunissen EL, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.891811eng
hcfmusp.relation.referenceThornton SL, 2015, ANN EMERG MED, V66, P343, DOI 10.1016/j.annemergmed.2015.05.021eng
hcfmusp.relation.referenceTrecki J, 2015, NEW ENGL J MED, V373, P103, DOI 10.1056/NEJMp1505328eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationac4f0b14-3d4a-4f58-a099-680747557b8f
relation.isAuthorOfPublication414cce5b-71d3-4cc2-92b1-5ac2c43d1660
relation.isAuthorOfPublication206d326d-45a0-47eb-9974-c48a7a98d564
relation.isAuthorOfPublication55d7e200-026a-4b23-8af0-eb5f630dea4c
relation.isAuthorOfPublication705f247c-4172-4359-aea1-246263fa9eb1
relation.isAuthorOfPublication9f0c2bff-a323-46a3-af33-5616c46f14d8
relation.isAuthorOfPublication879957ea-41f8-4392-9861-7b240c3c2664
relation.isAuthorOfPublication6f026b82-161c-477a-b929-8c741fe9efff
relation.isAuthorOfPublication.latestForDiscoveryac4f0b14-3d4a-4f58-a099-680747557b8f
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_OLIVEIRA_Toxicity_of_Synthetic_Cannabinoids_in_K2Spice_A_Systematic_2023.PDF
Tamanho:
1.43 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MLS
Artigos e Materiais de Revistas Científicas - HC/IPer
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/23
Artigos e Materiais de Revistas Científicas - LIM/40